Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06206837 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
A Phase 1 study of Breast Cancer, sponsored by Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 20
- Study locations
NCT06206837 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 71 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06206837, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Conditions Studied
Interventions
- DRUG PF-07220060
- DRUG vepdegestrant
Study Locations (20)
California
- Hoag Health Center Irvine - Irvine
- Hoag Hospital Irvine - Irvine
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford Cancer Center - Palo Alto
- Stanford Cancer Institute - Clinical Trials Office - Palo Alto
- Stanford Women's Cancer Center - Palo Alto
- UCSF Medical Center at Mission Bay - San Francisco
Colorado
- UCHealth Poudre Valley Hospital - Fort Collins
- UCHealth Harmony - Fort Collins
- UCHealth Greeley Hospital - Greeley
- UCHealth - Medical Center of the Rockies - Loveland
Connecticut
- Smilow Cancer Hospital - Yale New Haven Health - New Haven
- Yale - New Haven Hospital - Yale Cancer Center - New Haven
- Smilow Cancer Hospital Phase 1 Unit - New Haven
- Smilow Cancer Hospital - Trumbull - Trumbull
Arkansas
- Highlands Oncology - Fayetteville
- Highlands Oncology - Rogers
- Highlands Oncology Group - Springdale
Michigan
- START Midwest - Grand Rapids
New Jersey
- MSK Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2026-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06206837
The ClinicalTrials.gov registry entry for NCT06206837 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which PF-07220060 is the first listed.
NCT06206837 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06206837 about?
NCT06206837 is a clinical study titled "A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.". The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other pa...
What is the current status of trial NCT06206837?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2024-02-19. Estimated completion is 2026-09-07.
What conditions does trial NCT06206837 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06206837?
The interventions under investigation include: PF-07220060 (DRUG), vepdegestrant (DRUG).
Who is sponsoring clinical trial NCT06206837?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06206837 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.